Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor Agonist Prior to Anesthesia.

A clinical trial, NCT06654219, aims to investigate the protective benefits of a clear liquid diet (CLD) on residual gastric content (RGC) in patients taking Glucagon Like Peptide-1 Receptor Agonist (GLP-1 RA) prior to anesthesia. The study will assess the impact of prolonged fasting on RGC, thirst, hunger, and anxiety, as well as symptoms like nausea, vomiting, and abdominal pain. The trial will also examine the association between GLP-1 RA therapy duration and dosing with RGC. The trial is not yet recruiting participants and is set to conclude on November 1, 2025. [Extracted from the article]